Position in NVS
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$695,680
+$71,086 QoQ
Shares Held
4,439
+8.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#755
of 1,603 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Composition Wealth, LLC holds $115,127,781 across 14 Drug Manufacturers - General names. NVS ranks #10 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
114,607 | $29,106,739 | |
| 2 | LLY |
ELI LILLY & Co
|
22,959 | $27,537,715 | |
| 3 | ABBV |
AbbVie Inc.
|
67,878 | $17,080,819 | |
| 4 | MRK |
Merck & Co., Inc.
|
99,815 | $12,826,227 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
111,561 | $6,428,144 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
45,430 | $5,739,626 | |
| 7 | PFE |
Pfizer Inc
|
233,380 | $5,619,790 | |
| 8 | AZN |
Astrazeneca PLC
|
22,766 | $4,316,888 |
All Filings in NVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $695,680 | 4,439 | Shares | Sole | 2026-07-22 | |
| 2026-03-31 | $624,594 | 4,089 | Shares | Sole | 2026-04-08 | |
| 2025-12-31 | $503,363 | 3,651 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $464,100 | 3,619 | Shares | Sole | 2025-10-20 | |
| 2025-06-30 | $398,243 | 3,291 | Shares | Sole | 2025-07-22 | |
| No filing history on record for this holder in this stock. | ||||||